Lazard Asset Management
NRIX icon

Lazard Asset Management’s Nurix Therapeutics NRIX Stock Holding History

Lazard Asset Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,155
Closed -$40K – 2485
2024
Q4 		$40K Hold
2,155
– – ﹤0.01% 2016
2024
Q3 		$48K Sell
2,155
-2,563
-54% -$58.1K ﹤0.01% 1928
2024
Q2 		$98K Buy
+4,718
New +$73.5K ﹤0.01% 1757
2023
Q4 		– Sell
-5,674
Closed -$44K – 2391
2023
Q3 		$44K Sell
5,674
-2,986
-34% -$27.3K ﹤0.01% 1894
2023
Q2 		$86K Buy
8,660
+5,781
+201% +$59K ﹤0.01% 1638
2023
Q1 		$25K Buy
2,879
+1,779
+162% +$18.5K ﹤0.01% 2003
2022
Q4 		$11K Buy
+1,100
New +$13.3K ﹤0.01% 2191

Other funds holding NRIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Lazard Asset Management's NRIX Position: Q1 2025 in Review

Lazard Asset Management sold out of Nurix Therapeutics (NRIX) in Q1 2025, closing a stake of 2,155 shares — an estimated $40K sold.

Lazard Asset Management first reported a position in NRIX in Q4 2022 and held it in 7 quarters. The position peaked at $98K in Q2 2024. 170 funds tracked by Wall St. Rank hold NRIX as of Q1 2025.

  • Lazard Asset Management reported no remaining Nurix Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Lazard Asset Management sold 2,155 Nurix Therapeutics shares in Q1 2025, an estimated $40K.
  • Lazard Asset Management first reported a position in Nurix Therapeutics in Q4 2022 and held it in 7 quarters.
  • Lazard Asset Management's Nurix Therapeutics position peaked at $98K in Q2 2024.
  • 170 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2025.

Based on Lazard Asset Management's 13F filing for Q1 2025, filed 15 May 2025.